Hims and Hers just shut down its dermatology business after stock slump on FDA's weight-loss drug decision
Portfolio Pulse from
Hims and Hers is closing its dermatology business, including the skincare site Apostrophe, to centralize its teledermatology offerings. This decision follows a stock slump after the FDA's weight-loss drug decision.
March 07, 2025 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Hims and Hers is closing its dermatology business, including Apostrophe, to centralize its teledermatology offerings. This move comes after a stock slump linked to the FDA's weight-loss drug decision.
The closure of the dermatology business indicates a strategic shift in response to financial pressures, likely exacerbated by the FDA's decision impacting stock prices. This suggests potential short-term negative impact on HIMS stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100